Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;40(4):736-750.
doi: 10.1111/liv.14390. Epub 2020 Feb 19.

Collagen biology and non-invasive biomarkers of liver fibrosis

Morten A Karsdal  1 , Samuel J Daniels  1 , Signe Holm Nielsen  1 , Cecilie Bager  1 , Daniel G K Rasmussen  1 , Rohit Loomba  2 , Rambabu Surabattula  2 , Ida Falk Villesen  1   3 , Yi Luo  4 , Diane Shevell  4 , Natasja S Gudmann  1 , Mette J Nielsen  1 , Jacob George  5 , Rose Christian  4 , Diana J Leeming  1 , Detlef Schuppan  6   7
Affiliations
Review

Collagen biology and non-invasive biomarkers of liver fibrosis

Morten A Karsdal et al. Liver Int. 2020 Apr.

Abstract

There is an unmet need for high-quality liquid biomarkers that can safely and reproducibly predict the stage of fibrosis and the outcomes of chronic liver disease (CLD). The requirement for such markers has intensified because of the high global prevalence of diseases such as non-alcoholic fatty liver disease (NAFLD). In particular, there is a need for diagnostic and prognostic tools, as well as predictive biomarkers that reflect the efficacy of interventions, as described by the BEST criteria (Biomarkers, EndpointS, and other Tools Resource). This review covers the various liver collagens, their functional role in tissue homeostasis and delineates the common nomenclature for biomarkers based on BEST criteria. It addresses the common confounders affecting serological biomarkers, and describes defined collagen epitope biomarkers that originate from the dynamic processes of extracellular matrix (ECM) remodelling during liver injury.

Keywords: HBV; HCV; NAFLD; NASH; biomarker; cirrhosis; collagen; fibrogenesis; fibrolysis; fibrosis; liver; monitoring; non-invasive; peptide; plasma; procollagen; serum; treatment.

PubMed Disclaimer

References

REFERENCES

    1. Caballería L, Pera G, Arteaga I, et al. High prevalence of liver fibrosis among European adults with unknown liver disease: a population-based study. Clin Gastroenterol Hepatol. 2018;16:1138-1145.e5.
    1. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med. 2006;10:76-99.
    1. Schuppan D, Ashfaq-Khan M, Yang AT, Kim YO. Liver fibrosis: direct antifibrotic agents and targeted therapies. Matrix Biol. 2018;68-69:435-451.
    1. Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69:896-904.
    1. Guirguis J, Chhatwal J, Dasarathy J, et al. Clinical impact of alcohol-related cirrhosis in the next decade: estimates based on current epidemiological trends in the United States. Alcohol Clin Exp Res. 2015;39:2085-2094.

LinkOut - more resources